公司資料
Capricor Therapeutics 股價、新聞與催化劑
- 股票代碼:
- CAPR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.45 USD (+12.03%)
收盤價
最後更新: 2026年8月17日
1.58B USD
市值
股價為何變動
As of Aug 17, 2026, CAPR closed up 12.0% at $7.45. No new same-company headline was identified in the current news window.
公司概覽
Cell Therapy for Duchenne Muscular Dystrophy
Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.
Deramiocel
The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling.
HOPE-3 Evidence
The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
未來催化劑
- FDA decision on the deramiocel BLA for Duchenne muscular dystrophy.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。